Barrett Esophagus (Barrett's Esophagus)

A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.

Also Known As:

Networked: 1656 relevant articles (89 outcomes, 255 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Adenocarcinoma
2.	Neoplasms (Cancer)
3.	Gastroesophageal Reflux (GERD)
4.	Esophageal Neoplasms (Esophageal Cancer)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Sharma, Prateek: 35 articles (10/2015 - 07/2002)
2.	Wang, Kenneth K: 29 articles (10/2015 - 03/2002)
3.	Shaheen, Nicholas J: 28 articles (12/2015 - 11/2003)
4.	Reid, Brian J: 28 articles (11/2015 - 04/2003)
5.	Souza, Rhonda F: 26 articles (08/2015 - 02/2002)
6.	Vaughan, Thomas L: 25 articles (11/2015 - 05/2003)
7.	Siersema, Peter D: 23 articles (12/2015 - 01/2002)
8.	Odze, Robert D: 23 articles (09/2015 - 08/2002)
9.	Blount, Patricia L: 20 articles (01/2015 - 04/2003)
10.	Lightdale, Charles J: 19 articles (12/2015 - 10/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Barrett Esophagus:

1.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/01/2000 - "This study demonstrates that ALA-induced PDT provides safe and effective ablation therapy for Barrett's esophagus and is particularly useful against dysplasia." 09/01/2000 - "Histologic improvement in dysplasia is an inadequate endpoint for PDT in patients with Barrett's esophagus." 03/01/2008 - "This study assessed whether pretreatment variables, including prior endoscopic therapy for Barrett's esophagus, are associated with post-PDT stricturing. " 03/01/2004 - "The aim of this study was to establish the optimum dosage regime for ALA-PDT for Barrett's esophagus. " 01/01/2000 - "The aim of this study was to assess the value of PDT in the treatment of Barrett's esophagus with low-grade dysplasia (LGD). "
2.	Proton Pump InhibitorsIBA 10/01/2004 - "Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus." 07/01/2003 - "The only randomized multi-center prospective trial in the treatment of Barrett's esophagus with high-grade dysplasia has established that the treatment eliminates high-grade dysplasia better than administration of proton pump inhibitors alone. " 06/01/2015 - "The Effect of Proton Pump Inhibitors on Barrett's Esophagus." 05/01/2014 - "Side effects of proton-pump inhibitors: another reason to indicate anti-reflux surgery for Barrett's esophagus?" 01/01/2014 - "Proton Pump Inhibitors: The Culprit for Barrett's Esophagus?"
3.	Aminocaproic Acids (EAC)FDA LinkGeneric 06/01/2014 - "The purpose of this study was to assess the cost-effectiveness of PPIs for the prevention of EAC in Barrett's esophagus without reflux. " 12/01/2013 - "The aim of the present study was to compare the disorder strength measured by PWS in normal squamous epithelium in the proximal esophagus to determine whether nanoscale architectural differences are detectable in the field area of EAC and Barrett's esophagus. " 10/01/2013 - "In conclusion, this study provides evidence that MHC rs9257809 and FOXF1 rs9936833 variants, associated with Barrett's esophagus, also increase ESCC and EAC susceptibility in Caucasians. " 01/01/2013 - "These inconsistencies may partly result from pathological and/or molecular heterogeneity in both Barrett's esophagus and EAC, but may also result from differences in study designs or different choices of comparator tissues. " 07/01/2012 - "Recent studies found the risk of progression from Barrett's esophagus to EAC to be significantly lower than previously reported, raising concerns regarding the limitations of current surveillance strategies. "
4.	Omeprazole (Esomeprazole)FDA LinkGeneric 01/01/2003 - "The aim of this study is to assess the efficacy of esomeprazole, a new potent PPI, on symptom relief and intraesophageal and intragastric acid suppression in patients with Barrett's esophagus (BE). " 01/01/2003 - "Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus." 01/01/2010 - "This study suggests the possibility of combined therapy with omeprazole and the preparation of UDCA (Ursosan) as a promising means for hemopreventciya Barrett's esophagus in the elderly." 09/01/2006 - "Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial." 08/01/2013 - "Patients with GEJSIM and Barrett's esophagus underwent upper endoscopy with 48-h wireless pH capsule while on once daily 20 mg omeprazole for at least 1 week. "
5.	Cimetidine (Biomet)FDA LinkGeneric 01/01/1984 - "This long-term study in a patient with Barrett's esophagus showed 1) that cimetidine can be effective in treating such patients; 2) the prophylactic value of multitherapy as a maintenance regimen, and 3) the importance of careful follow-up." 02/01/1987 - "To evaluate long-term medical therapy in patients with Barrett's esophagus, six patients were studied before and after long-term therapy with cimetidine for a mean period of 11.7 months. " 04/01/1983 - "Treatment of the complications of Barrett's esophagus is essentially surgical, although cimetidine has been shown to be effective for healing of Barrett's ulcer. " 06/01/1981 - "The results indicate the potential use of cimetidine for enhanced visualization of Meckel's diverticulum, Barrett's esophagus, and the stomach, with 99mTc-pertechnetate." 04/01/1987 - "The effect of the H2 receptor antagonists, cimetidine and ranitidine, on Barrett's esophagus was assessed in a retrospective study. "
6.	Biological Markers (Surrogate Marker)IBA 07/01/2005 - "We summarize some of the important advances in that regard including: improved understanding in areas of epidemiology of those with Barrett's esophagus, identification of the pathways responsible for dysplastic and metaplastic development, selection of patient populations who would most benefit from surveillance protocols, and identification of biomarkers signifying progression of metaplastic changes. " 05/01/2012 - "This study aims to compare some validated biomarkers of malignancy (Ki-67, p53, and apoptosis) between 2 groups of patients with Barrett's esophagus (BE) undergoing randomly medical or surgical treatment. " 01/01/2012 - "These studies reveal many novel, potential targets for new therapies and illustrate the utility of incorporating these epigenetic changes as biomarkers during endoscopic surveillance interval for patients with Barrett's esophagus." 06/01/2011 - "Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study." 05/15/2009 - "A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus."
7.	Acetic Acid (Vinegar)FDA LinkGeneric 09/01/2014 - "Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video)." 12/01/2010 - "Barrett esophagus: acetic acid dye spray shows efficacy for detecting neoplasia." 09/01/2014 - "This study aimed to investigate the effectiveness of acetic acid chromoendoscopy in a Barrett's esophagus surveillance population. " 01/01/2014 - "Acetic acid compared with i-scan imaging for detecting Barrett's esophagus: a randomized, comparative trial." 07/01/2006 - "Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett's esophagus: a prospective randomized trial with crossover design."
8.	lansoprazole (Prevacid)FDA LinkGeneric 05/01/1998 - "In this prospective trial, we studied patients with Barrett's esophagus by 24-h intraesophageal pH monitoring after having completely eliminated their reflux symptoms with lansoprazole, to determine whether they had achieved normalization of intraesophageal pH. Thirty patients with Barrett's esophagus, all of whom had presented with reflux symptoms, were treated with lansoprazole (15-30 mg/day) until they were asymptomatic. " 05/01/1998 - "Complete symptom eradication with lansoprazole (15-30 mg daily) in patients with Barrett's esophagus does not guarantee normalization of intraesophageal pH profile. " 10/01/1994 - "Patients with Barrett's esophagus at least 3 cm long and with specialized columnar epithelium were treated with 60 mg of lansoprazole each morning. " 10/01/1994 - "Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus." 10/01/1994 - "The objective of this study was to assess the impact of long-term, high-dose lansoprazole, a proton pump inhibitor, on Barrett's esophagus. "
9.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/01/2013 - "NSAIDs modulate clonal evolution in Barrett's esophagus." 02/06/2014 - "Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus." 05/01/2006 - "Barrett's esophagus and esophageal adenocarcinoma patients were less likely than controls to have used NSAIDs. " 06/01/2003 - "However, these cost values are sensitive to variations in the costs of chemoprevention, incidence of cancer in patients with Barrett's esophagus, and efficacy of NSAIDs in reducing the incidence of cancer, which can shift the ICER into a cost range that is prohibitively expensive. " 06/01/2013 - "Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce cancer risk, including risk of progression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EA). "
10.	Carbon DioxideIBA 07/01/2015 - "The aim of this study was to assess the long-term safety and efficacy of carbon dioxide (CO2) cryotherapy as primary or rescue treatment for Barrett's esophagus with high grade dysplasia (HGD) or neoplasia. " 07/01/2015 - "Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett's esophagus." 07/01/2015 - "Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett's esophagus." 05/01/2011 - "A pilot study of endoscopic spray cryotherapy by pressurized carbon dioxide gas for Barrett's esophagus."

Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy) 07/01/2011 - "Radiofrequency ablation is effective for the treatment of high-grade dysplasia in Barrett's esophagus after failed photodynamic therapy." 11/01/2010 - "Photodynamic therapy is effective for the ablation of dysplasia in Barrett's esophagus, although the frequency of adverse events is quite high. " 04/01/2008 - "How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus." 11/01/2004 - "Photodynamic therapy appears to be effective in ablating high-grade dysplasia in Barrett's esophagus. " 07/01/2004 - "Photodynamic therapy was also effective in removing Barrett epithelium. "
2.	Esophagectomy 01/01/2010 - "Endoscopic treatments offer safe and effective alternatives to esophagectomy for patients with Barrett's esophagus and high grade dysplasia. " 03/01/2009 - "Esophagectomy will remain the gold-standard treatment of Barrett's esophagus with high-grade dysplasia until clinical research validates the role of endoscopic therapies. " 05/01/2015 - "Biopsy samples from post-esophagectomy patients provide a valuable resource to study the early stages of Barrett's esophagus." 11/01/2009 - "The aim of this study was to determine the contribution of preoperative gastric secretory and hormonal response, to the appearance of Barrett's esophagus in the esophageal stump following subtotal esophagectomy. " 06/01/2015 - "Numerous histological mimics of high-grade dysplasia in Barrett's esophagus predispose to overdiagnosis and potential serious mismanagement, including unnecessary esophagectomy. "
3.	Cryotherapy (Therapy, Cold) 04/01/2010 - "Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia." 09/01/2015 - "Salvage cryotherapy after failed radiofrequency ablation for Barrett's esophagus-related dysplasia is safe and effective." 07/01/2015 - "Endoscopic cryotherapy has been used successfully for the ablation of Barrett's esophagus but outcome data are limited. " 04/01/2015 - "Cryotherapy is a relatively novel ablation modality for the endoscopic ablation of Barrett's esophagus (BE). " 12/01/2013 - "The use of cryotherapy for treatment of barrett esophagus."
4.	Argon Plasma Coagulation 07/01/2000 - "High power setting argon plasma coagulation combined with intensive acid suppression is an effective treatment for the total endoscopic ablation of Barrett's esophagus, at least in the short term. " 01/01/2004 - "Argon plasma coagulation of Barrett's esophagus is safe and effective. " 12/01/2009 - "The purpose of this study is to determine the efficacy of endoscopic argon plasma coagulation (APC) for ablation of Barrett's esophagus in a prospective randomized controlled trial in two university teaching hospitals. " 12/01/2007 - "To determine the efficacy of endoscopic argon plasma coagulation (APC) for ablation of Barrett esophagus. " 11/01/2013 - "Argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus: late outcomes from two randomized trials."
5.	Chemoprevention 07/15/2014 - "Elucidation of this molecular pathway for UDCA protection provides rationale for clinical trials on UDCA for chemoprevention in Barrett's esophagus. " 10/01/2008 - "The role of chemoprevention in Barrett's esophagus still awaits the results of ongoing clinical trials in the United Kingdom and North America." 10/01/2008 - "While this study indicates that there is a strong interest among Barrett's esophagus patients for chemoprevention, it is still premature for our patients to embark on such an approach. " 01/01/2008 - "Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial." 06/01/2007 - "Newer treatment options for Barrett's esophagus are being developed in all areas, including endoscopic therapy, surgery, and chemoprevention trials."